FDA Grants Fast Track Designation to CRB-701 for the Treatment of R/R Metastatic Cervical Cancer December 10, 2024
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous NSCLC With EGFR Mutations December 10, 2024
FDA granted RMAT designation to acimtamig and AlloNK (AB101) for the treatment of R/R HL December 10, 2024
Outcomes of Type D meeting with FDA to obtain guidance on the design of a Ph 3 study of VCN-01 + chemo in metastatic pancreatic adenocarcinoma (PDAC) announced December 10, 2024
AdAPT-001 Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment December 10, 2024
FDA Orphan Drug Designation for Azeliragon for the Treatment of Brain Metastasis From Breast Cancer December 10, 2024
Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer December 10, 2024
FDA Approves BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ NSCLC Based on Safety and Efficacy Data From the eNRGy Study December 10, 2024
